Drug Trial Radar · NCT07696091
Study on Drug Interactions Affecting the Pharmacokinetics of RSS0343 Tablet
Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jul 2026
Primary completion
Sep 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- Reistone Biopharma Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jul 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a single-center, single-sequence, self-controlled, open design, aiming to investigate the effects of rifampicin and clarithromycin on the pharmacokinetics of RSS0343 in humans.
Conditions
- Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease
Interventions
RSS0343 Tablet; Rifampicin CapsulesDrug
RSS0343 Tablet; Rifampicin Capsules
RSS0343 Tablet; Clarithromycin TabletsDrug
RSS0343 Tablet; Clarithromycin Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax; The maximum plasma concentrationTime frame: Day1-Day38
- AUC0-t; From time 0 to the area under the blood drug concentration-time curve corresponding to the last quantifiable concentrationTime frame: Day1-Day38
- AUC0-inf;Area under the concentration curve from time 0 to extrapolated infinite timeTime frame: Day1-Day38
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.